Comparison of Combination Therapy of Adenosine and Nitroprusside with Adenosine Alone in the Treatment of Angiographic No-Reflow Phenomenon

Catheterization and Cardiovascular Interventions

Volumn 61, Issue 4, 2004, Pages 484-491

  Barcin, Cem ^a   Denktas, Ali E ^a   Lennon, Ryan J ^a   Hammes, LaVon ^a   Higano, Stuart T ^a   Holmes Jr , David R ^a   Garratt, Kirk N ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adenosine; Coronary; Coronary blood flow; Percutaneous coronary intervention

Indexed keywords

ADENOSINE; ATROPINE; CALCIUM CHANNEL BLOCKING AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; NICARDIPINE; NITROPRUSSIDE SODIUM; VERAPAMIL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; SIDE EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADENOSINE; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROPRUSSIDE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 1842531998     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20010     Document Type: Article

References (39)

1. Kloner RA. No reflow revisited. J Am Coll Cardiol 1989;14: 1814-1815.
2. Abbo KM, Dooris M, Glazier S, O'neill WW, Byrd D, Grines CL, Safian RD. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-782.
3. Leopold JA, Berger JC, Cuppels LA, Berg JD, Jacobs AK. No-reflow during coronary intervention: observations and implications. Circulation 2000;102:(Suppl 2)644.
4. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carozza JP Jr, Kuntz RE, Baim DS. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 1994;89:2514-2518.
5. Sharma SK, Dangas G, Mehran R, Duvvuri S, Kini A, Cocke TP, Kakarala V, Cohan AM, Marmur JD, Ambrose JA. Risk factors for the development of slow flow during rotational coronary atherectomy. Am J Cardiol 1997;80:219-222.
6. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takiuchi S, Negoro S, Nakatsuchi Y, Taniyama Y, Higashino Y, Fujii K, Minamino T. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993-1999.
7. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Kakai K. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996;132:959-963.
8. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, Nishikawa N, Higashino Y, Fujii K, Minamino T. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997;30:1193-1199.
9. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FU, Grines CL, O'Neill WW, Safian RD. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996;39:113-118.
10. Kemp BK, Cocks TM. Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors. Br J Pharmacol 1999;126:1796-1800.
11. Hein TW, Kuo L. cAMP-independent dilation of coronary arterioles to adenosine: role of nitric oxide, G proteins, and K(ATP) channels. Circ Res 1999;85:634-642.
12. Hillegas WB, Dean NA, Liao L, Rhinehart HG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001;37:1335-1343.
13. Dodge JT Jr, Rizzo M, Nykiel M, Altmann J, Hobkirk K, Brennan M, Gibson CM. Impact of injection rate on the Thrombolysis in Myocardial Infarction (TIMI) trial frame count. Am J Cardiol 1998;81:1268-1270.
14. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001;22:729-739.
15. Glyn MC, Ward BJ. Contraction in cardiac endothelial cells contributes to changes in capillary dimensions following ischaemia and reperfusion. Cardiovasc Res 2000;48:346-356.
16. Ma XL, Tsao PS, Viehman GE, Lefer AM. Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion-reperfused cat coronary artery. Circ Res 1991;69:95-106.
17. Murohara T, Buerke M, Lefer AM. Polymorphonuclear leukocyte-induced vasocontraction and endothelial dysfunction: role of selectins. Arterioscler Thromb 1994;14:1509-1519.
18. Duilio C, Ambrosio G, Kuppusamy P, DiPaula A, Becker LC, Zweier JL. Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol 2001;280:H2649-H2657.
19. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994;28:1301-1311.
20. Galiuto L, DeMaria AN, del Balzo U, May-Newman K, Flaim SF, Wolf PL, Kirchengast M, Iliceto S. Ischemia-reperfusion injury at the microvascular level: treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation 2000;102:3111-3116.
21. Wang WZ, Guo SZ, Tsai TM, Anderson GL, Miller FN. Platelet-activating factor contributes to postischemic vasospasm. J Surg Res 2000;89:139-146.
22. Hasdai D, Holmes DR Jr, Garratt KN, Edwards WD, Lerman A. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 1997;95: 357-362.
23. Rimoldi O, Spyrou N, Foale R, Hackett DR, Gregorini L, Camici PG. Limitation of coronary reserve after successful angioplasty is prevented by oral pretreatment with an alpha1-adrenergic antagonist. J Cardiovasc Pharmacol 2000;36:310-315.
24. Gregorini L, Marco J, Kozakova M, Palombo C, Anguissola GB, Marco I, Bernies M, Cassagneau B, Distnate A, Bossi IM, Fajadet J, Heusch G. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999;99:482-490.
25. Kyriakides ZS, Kremastinos DT, Psychari SN, Kolettis T, Sbarouni E, Webb DJ. Coronary vasoconstriction after coronary angioplasty is attenuated by endothelin a receptor antagonism. Am J Cardiol 2001;87:1011-1013.
26. Leosco D, Fineschi M, Pierli C, Fiaschi A, Ferrara N, Bianco S, Longobardi G, Piasni E, Bravi A, Rengo F. Intracoronary serotonin release after high-pressure coronary stenting. Am J Cardiol 1999;84:1317-1322.
27. Michaels AD, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol 2000;85:50B-60B.
28. Akatsuka Y, Egashira K, Katsuda Y, et al. ATP sensitive potassium channels are involved in adenosine A2 receptor mediated coronary vasodilatation in the dog. Cardiovasc Res 1994;28:906-911.
29. Belardinelli L, Shryock JC, Snowdy S, Zhang Y, Manopoli A, Iozza G, Ognini E, Olsson RA, Dennis DM. The A2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther 1998;284:1066-1073.
30. Fischell TA, Carter AJ, Foster MT, Hemsall K, DeVries J, Kim DH, Kloustra A. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998;45:360-365.
31. Sdringola S, Assali A, Ghani M, Yepes A, Rosales O, Schroth GW, Fujise K, Anderson HV, Smalling RW. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv 2000;51:394-399.
32. Tiede JD, Brady PA, Garratt KN, Holmes DR. Resolution of the "no-reflow" phenomenon with intracoronary administration of adenosine. J Interv Cardiol 2000;13:15-18.
33. Assali AR, Sdringola S, Ghani M, Denktas AE, Yepes A, Hanna GP, Schroth G, Fujise K, Anderson HV, Smalling RW, Rosales OR. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc Interv 2000;51:27-31.
34. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-2159.
35. Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997;280:301-309.
36. Velasco CE, Jackson EK, Morrow JA, Vitola JV, Inagami T, Formen MB. Intravenous adenosine suppresses cardiac release of endothelin after myocardial ischaemia and reperfusion. Cardiovasc Res 1993;27:121-128.
37. Abrams J. Beneficial actions of nitrates in cardiovascular disease. Am J Cardiol 1996;77:31C-37C.
38. Kurz MA, Lamping KG, Bates JN, Eastham JL, Marcuc ML, Harrison DG. Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res 1991;68: 847-855.
39. Harrison DG, Bates JN. The nitrovasodilators: new ideas about old drugs. Circulation 1993;87:1461-1467.